|
Feb 24
|
BioCryst: Q4 Earnings Snapshot
|
|
Feb 24
|
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
|
|
Feb 24
|
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
|
|
Feb 19
|
BioCryst to Present at Upcoming Investor Conferences
|
|
Feb 17
|
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 12
|
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
|
|
Feb 10
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Feb 10
|
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
|
|
Feb 10
|
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
|
|
Jan 14
|
BioCryst price target raised to $12 from $10 at Evercore ISI
|
|
Jan 10
|
Exploring High Growth Tech Stocks In January 2025
|
|
Jan 10
|
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
|